Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer

Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer

Abstract Cyclin-dependent kinase (CDK) 4/6 inhibitors have significantly improved overall and progression free survival of patients with metastatic breast cancer, but their effect on short and long-term kidney function is unknown. We found that early, mild estimated glomerular filtration rate (eGFR)...

Full description

Bibliographic Details
Main Authors: Paul E. Hanna, Ian A. Strohbehn, Daiana Moreno, Destiny Harden, Rituvanthikaa Seethapathy, Rani Sawtell, Qiyu Wang, Tianqi Ouyang, Nurit Katz-Agranov, James Dinulos, Seth A. Wander, Shruti Gupta, Meghan E. Sise
Format: Article
Language:English
Published: Nature Portfolio 2023-08-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-023-00576-5

Internet

https://doi.org/10.1038/s41523-023-00576-5

Similar Items